Navigation Links
Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
Date:4/3/2008

WAYNE, Pa., April 3, 2008 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced that its Sonomed, Inc. subsidiary received approval from the State Food and Drug Administration within the People's Republic of China to market the PacScan(R) and E/Z-Scan(R) series of products in that country. The PacScan(R) series consists of A-scans, pachymeters, and combination systems used in both cataract and refractive surgery. The E/Z- Scan(R) series consists of both B-scan and A/B-scan systems for enhanced diagnostic capabilities. Both systems are widely marketed internationally and have become some of the best-selling ophthalmic biometry and ultrasound imaging systems in the world.

The company has immediate plans to market both series of instruments through its two existing distributors in mainland China, the Hwa-In Group and Shenzhen K&K, and also plans to increase its direct support network to assist distributors, attend regional meetings, and provide training as needed.

"Sonomed was well known and respected in the People's Republic of China prior to Medical Device Registration requirements and we look forward to re- introducing our latest line of ophthalmic ultrasound products with similar success," said Barry Durante, President of Sonomed, Inc. "These instruments will provide physicians the opportunity to offer a safe and accurate ultrasound examination to improve their diagnostic capability and patient surgical outcomes."

Sonomed, Inc. is a diagnostic ultrasound company specializing in the design, manufacture and distribution of instruments for ophthalmology. Sonomed is focused on providing quality instrumentation for ophthalmic physicians' offices, clinics and hospitals.

The PacScan(R) and E/Z-scan(R) will be showcased at the 8th International Congress of Ophthalmology and Optometry China (COOC) in Nanjing, China, on April 4 through April 6, 2008.

Founded in 1987, Escalon (http://www.escalonmed.com) develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. Escalon seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of Escalon's distribution capabilities, although any such partnerships or acquisitions may not occur. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Waterbury, Connecticut and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about Escalon's future prospects. They are based on Escalon's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

-- implement its growth and marketing strategies, improve upon the

operations of Escalon's business units, including the integration of

Drew's operations, the organization of the Drew business and the

integration of any acquisitions Escalon may undertake, if any, of which

there can be no assurance,

-- implement cost reductions,

-- generate cash,

-- identify, finance and enter into business relationships and

acquisitions.

Other factors include uncertainties and risks related to:

-- new product development, commercialization, manufacturing and market

acceptance of new products,

-- marketing acceptance of existing products in new markets,

-- research and development activities, including failure to demonstrate

clinical efficacy,

-- delays by regulatory authorities, scientific and technical advances by

Escalon or third parties,

-- introduction of competitive products,

-- third party reimbursement and physician training, and

-- general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Escalon's report on Form 10- K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.


'/>"/>
SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Escalon(R) Announces Executive Promotions
2. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
3. Escalon(R) Reports First Quarter Fiscal 2008 Results
4. Escalon(R) Reports Financial Results for 2007 Fiscal Year
5. NUCRYST Announces Senior Management Change
6. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
7. Medical Records Institute Announces New TEPR Award for EMRs Best Meeting Medicolegal Requirements
8. East Ridge Retirement Village Announces Enhancement Plan
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index
10. The Quantum Group Announces Increased Patient Enrollment Following Medicare Advantage Open Enrollment Period
11. Selective Insurance Group Announces Officer Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: